FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210659081> ?p ?o ?g. }

• W4210659081 endingPage "100526" @default.
• W4210659081 startingPage "100526" @default.
• W4210659081 abstract "Introduction of EGFR-TKI has changed the treatment paradigm for NSCLC patient with activating mutations of EGFR exons 18–21, replacing chemotherapy as standard first line treatment. Given the delays in molecular study results we sometimes face the need to start treatment in very symptomatic patients with high tumor burden. The reason for this retrospective study is to analyze the survival impact of performing an induction cytotoxic therapy until obtaining the molecular profile (EGFR mutation), followed by targeted therapy. This is a retrospective analysis of 31 patients who did upfront chemotherapy (ChT) before switching to EGFR TKI upon the molecular profile result. The calculated survival endpoints were progression-free survival (PFS), duration of TKI response and overall survival (OS). All patients were treated with upfront chemotherapy with a median of one cycle (range 1–3) followed by a first generation EGFR-TKI. Median PFS was 13 months (95% CI, 6.6–19.4) and median OS 33 months (95% CI, 11.9–54.0). After first line progression 14 patients were treated with Osimertinib. In this subgroup median OS was 52 months (95% CI, 34.0–69.9). In the multivariable Cox model, only body mass index retained independent prognostic significance for progression-free survival (p = 0.045). Survival outcomes in this cohort are in line with published data regarding first generation EGFR-TKI, both in terms of PFS and OS. Despite the limitations of this study, starting with upfront chemotherapy doesn't seem detrimental in terms of survival outcomes, with the potential advantage of symptomatic control. To our knowledge, this is the first study to address this strategy, which requires further confirmation." @default.
• W4210659081 created "2022-02-08" @default.
• W4210659081 creator A5001703673 @default.
• W4210659081 creator A5029003907 @default.
• W4210659081 creator A5032661255 @default.
• W4210659081 creator A5039762109 @default.
• W4210659081 creator A5055990469 @default.
• W4210659081 creator A5079451020 @default.
• W4210659081 creator A5082015191 @default.
• W4210659081 creator A5085628661 @default.
• W4210659081 date "2022-01-01" @default.
• W4210659081 modified "2023-09-29" @default.
• W4210659081 title "Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study" @default.
• W4210659081 cites W1988856925 @default.
• W4210659081 cites W2096198395 @default.
• W4210659081 cites W2106787323 @default.
• W4210659081 cites W2111662961 @default.
• W4210659081 cites W2127985707 @default.
• W4210659081 cites W2129360604 @default.
• W4210659081 cites W2132157071 @default.
• W4210659081 cites W2154662831 @default.
• W4210659081 cites W2160982674 @default.
• W4210659081 cites W2166084034 @default.
• W4210659081 cites W2171139285 @default.
• W4210659081 cites W2206185841 @default.
• W4210659081 cites W2310000709 @default.
• W4210659081 cites W2760639821 @default.
• W4210659081 cites W2770828094 @default.
• W4210659081 cites W2784538417 @default.
• W4210659081 cites W2908470444 @default.
• W4210659081 cites W2921797044 @default.
• W4210659081 cites W2938245541 @default.
• W4210659081 cites W2945279909 @default.
• W4210659081 cites W2967398918 @default.
• W4210659081 cites W2981991856 @default.
• W4210659081 cites W2990041408 @default.
• W4210659081 cites W4205406222 @default.
• W4210659081 cites W4210394199 @default.
• W4210659081 doi "https://doi.org/10.1016/j.ctarc.2022.100526" @default.
• W4210659081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35114501" @default.
• W4210659081 hasPublicationYear "2022" @default.
• W4210659081 type Work @default.
• W4210659081 citedByCount "1" @default.
• W4210659081 countsByYear W42106590812023 @default.
• W4210659081 crossrefType "journal-article" @default.
• W4210659081 hasAuthorship W4210659081A5001703673 @default.
• W4210659081 hasAuthorship W4210659081A5029003907 @default.
• W4210659081 hasAuthorship W4210659081A5032661255 @default.
• W4210659081 hasAuthorship W4210659081A5039762109 @default.
• W4210659081 hasAuthorship W4210659081A5055990469 @default.
• W4210659081 hasAuthorship W4210659081A5079451020 @default.
• W4210659081 hasAuthorship W4210659081A5082015191 @default.
• W4210659081 hasAuthorship W4210659081A5085628661 @default.
• W4210659081 hasBestOaLocation W42106590811 @default.
• W4210659081 hasConcept C121608353 @default.
• W4210659081 hasConcept C126322002 @default.
• W4210659081 hasConcept C143998085 @default.
• W4210659081 hasConcept C167135981 @default.
• W4210659081 hasConcept C2776256026 @default.
• W4210659081 hasConcept C2776694085 @default.
• W4210659081 hasConcept C2777626846 @default.
• W4210659081 hasConcept C2778087573 @default.
• W4210659081 hasConcept C2779438470 @default.
• W4210659081 hasConcept C2780739268 @default.
• W4210659081 hasConcept C2781230642 @default.
• W4210659081 hasConcept C71924100 @default.
• W4210659081 hasConceptScore W4210659081C121608353 @default.
• W4210659081 hasConceptScore W4210659081C126322002 @default.
• W4210659081 hasConceptScore W4210659081C143998085 @default.
• W4210659081 hasConceptScore W4210659081C167135981 @default.
• W4210659081 hasConceptScore W4210659081C2776256026 @default.
• W4210659081 hasConceptScore W4210659081C2776694085 @default.
• W4210659081 hasConceptScore W4210659081C2777626846 @default.
• W4210659081 hasConceptScore W4210659081C2778087573 @default.
• W4210659081 hasConceptScore W4210659081C2779438470 @default.
• W4210659081 hasConceptScore W4210659081C2780739268 @default.
• W4210659081 hasConceptScore W4210659081C2781230642 @default.
• W4210659081 hasConceptScore W4210659081C71924100 @default.
• W4210659081 hasLocation W42106590811 @default.
• W4210659081 hasLocation W42106590812 @default.
• W4210659081 hasLocation W42106590813 @default.
• W4210659081 hasOpenAccess W4210659081 @default.
• W4210659081 hasPrimaryLocation W42106590811 @default.
• W4210659081 hasRelatedWork W1591408781 @default.
• W4210659081 hasRelatedWork W2055244776 @default.
• W4210659081 hasRelatedWork W2413020017 @default.
• W4210659081 hasRelatedWork W2593927093 @default.
• W4210659081 hasRelatedWork W2903819389 @default.
• W4210659081 hasRelatedWork W2921871143 @default.
• W4210659081 hasRelatedWork W3029222855 @default.
• W4210659081 hasRelatedWork W3036162643 @default.
• W4210659081 hasRelatedWork W4308323206 @default.
• W4210659081 hasRelatedWork W2597201175 @default.
• W4210659081 hasVolume "31" @default.
• W4210659081 isParatext "false" @default.
• W4210659081 isRetracted "false" @default.
• W4210659081 workType "article" @default.